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Abstract Choroideremia (CHM) is an X-linked retinal de-
generation of photoreceptors, the retinal pigment epithelium
(RPE) and choroid caused by loss of function mutations in
the CHM/REP1 gene that encodes Rab escort protein 1. As a
slowly progressing monogenic retinal degeneration with a
clearly identifiable phenotype and a reliable diagnosis,
CHM is an ideal candidate for gene therapy. We developed
a serotype 2 adeno-associated viral vector AAV2/2-CBA-
REP1, which expresses REP1 under control of CMV-
enhanced chicken β-actin promoter (CBA) augmented by
a Woodchuck hepatitis virus post-transcriptional regulatory
element. We show that the AAV2/2-CBA-REP1 vector pro-
vides strong and functional transgene expression in the D17
dog osteosarcoma cell line, CHM patient fibroblasts and
CHM mouse RPE cells in vitro and in vivo. The ability to
transduce human photoreceptors highly effectively with this
expression cassette was confirmed in AAV2/2-CBA-GFP
transduced human retinal explants ex vivo. Electroretinogram
(ERG) analysis of AAV2/2-CBA-REP1 and AAV2/2-CBA-
GFP-injected wild-type mouse eyes did not show toxic effects
resulting from REP1 overexpression. Subretinal injections of
AAV2/2-CBA-REP1 into CHM mouse retinas led to a signifi-
cant increase in a- and b-wave of ERG responses in comparison
to sham-injected eyes confirming that AAV2/2-CBA-REP1 is a
promising vector suitable for choroideremia gene therapy in
human clinical trials.
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Introduction
Choroideremia (CHM) is an X-linked retinal degeneration of
choroid, photoreceptors and retinal pigment epithelium (RPE)
affecting approximately one in 50,000 patients worldwide [1].
CHM is caused by the loss of function mutations in the
CHM/REP1 gene (Xq21.2) that encodes Rab escort protein
1 (REP1) [2, 3]. First symptoms, such as night blindness and
constriction of visual field, appear in young male patients and
slowly progress towards complete blindness by the fifth
decade. The pathogenesis of the disease is complex, involving
degeneration of photoreceptors and RPE, followed ultimately
by extreme thinning of the choroid [4, 5].
REP1 is important for the function of Rab proteins,
which are small Ras-related GTPases [6]. Rabs regulate
intracellular vesicular transport through association with
intracellular membranes via one or two prenyl groups and
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interaction with the effectors, which is dependent on con-
formational changes induced by GDP/GTP binding [7].
Together with Rab geranylgeranyl transferase, REP1 and
its homologue REP2 participate in prenylation of Rabs and
thus are vital for the functionality of Rabs [8]. REP2
(encoded by the CHML gene) is a close homologue of
REP1, which can compensate for the loss of REP1 in most
human tissues except the eye [9].
As a slowly progressing monogenic disorder, CHM is
potentially treatable by gene addition therapy. RPE and photo-
receptors are the layers that degenerate first in CHM with
deterioration of choroid at the later stages; thus, the optimal
gene therapy vector is required to target RPE and photorecep-
tors at the first instance. In our previous work, we generated a
conditional mouse knockout and showed that both RPE and
photoreceptors degenerate independently [5]. Similarly, path-
ological specimens from humans have shown evidence for
independent degeneration of rod photoreceptors over focal
regions where RPE appears normal [4, 10]. At the same time,
the rate of photoreceptor degeneration is enhanced when the
REP1 is ablated in both layers [5]. In our previous work, we
showed that a lentiviral vector pseudotyped with vesicular
stomatitis virus protein G provided strong and stable expres-
sion of the humanCHM/REP1 cDNA transgene in human and
mouse choroideremia cells, including RPE, which resulted in
an increase of prenylation activity [11]. However, lentiviral
vectors were not optimal for CHM treatment because trans-
duction of the neuroretina was limited to the injection site.
With a functional fovea, safety with regard to avoiding a
vector-related inflammatory reaction is of paramount impor-
tance. Two recent clinical trials had demonstrated that sero-
type 2 adeno-associated viral (AAV2) vectors have no long-
term retinal toxicity when administered at the dose range
1010–1011 genome particles [12, 13]. Importantly, in addition
to transducing the RPE, AAV2 is also known to target rod
photoreceptors efficiently in the non-human primate [14],
providing the ideal tropism for a CHM gene therapy strategy.
The aim of our study was to develop and test a suitable
AAV-based vector with CHM/REP1 cDNA transgene for
future CHM clinical trials. Specifically, we wished to optimise
the expression cassette of AAV2 so that we could enhance the
level of gene expression in photoreceptors without increasing
the overall dose of viral vector particles, which might have a
negative effect on patients who still have a fully functional
fovea.
Materials and methods
Mice
All animals used in this study were treated humanely in
accordance with the UK Home Office Regulations under
project licences 70/6176 and 70/7078. Mice were maintained
on a 12:12-h light/dark cycle. ChmNull/WT mice are carrier
females with choroideremia phenotype; these animals were
described in detail previously [15].
Construction and production of AAV vectors
Human CHM/REP1 cDNA was obtained from Frans
Cremers (Nijmegen Centre for Molecular Life Sciences,
Netherlands) and modified by the insertion of a Kozak
consensus sequence at the 5′-end. To generate pAAV2-
EFS-GFP and pAAV2-EFS-REP1, AAV backbone vector
plasmid pAAV-MCS was obtained from Stratagene as a
part of the AAV Helper-Free System. Plasmid pAAV2-
MCS contains 5′ and 3′ AAV2 inverted terminal repeats
(ITRs), CMV promoter, β-globin intron and human
growth hormone polyadenylation site. CMV promoter
and β-globin intron of pAAV-MCS were removed and
replaced with the EFS-EGFP or EFS-CHM/REP1 cDNA
cassette that was excised from pWPT-GFP and pWPT-
REP1, respectively [11]. EFS is a short version of
elongation factor 1-α promoter. The Woodchuck hepatitis
virus post-transcriptional regulator element (WPRE)
was excised from the plasmid pWPI (http://www.addgene.org)
and inserted downstream of the transgene (EGFP or CHM/
REP1 cDNA).
The pAAV2-CBA-GFP and pAAV2-CBA-REP1 vector
contained 5′ and 3′ ITRs, cytomegalovirus (CMV) enhanced
chicken β-actin (CBA) hybrid promoter, a modified WPRE
and bovine growth hormone polyadenylation sequence. The
modified WPRE included deletion of the We2 promoter/
enhancer and mutation of the We1 promoter [16] to prevent
expression of the viral X antigen [17]; the sequence was
previously used in patients in a US Food and Drug Adminis-
tration (FDA)-approved gene therapy clinical trial for Parkin-
son’s disease [18].
All viral batches were generated by Gene Detect
(Auckland, New Zealand) in order to use an optimised proto-
col and purification steps that could be scaled up for good
medical practice vector production at a later date. This ensured
that the final vector suspension matched as closely as possible
the product that would be used for a future clinical trial.
Plasmids pAAV2-EFS-GFP and pAAV2-EFS-REP1 were
used to produce AAV vector virions of serotype 2 (AAV2/2-
EFS-GFP and AAV2/2-EFS-REP1) and 5 (AAV2/5-EFS-GFP
and AAV2/5-EFS-REP1). Vectors pAAV2-CBA-GFP and
pAAV2-CBA-REP1 were used to produce AAV vectors of
serotype 2 (AAV2/-CBA-GFP and AAV2/2-CBA-REP1).
Titres (genomic particles per millilitre) were AAV2/2-EFS-
GFP (1.2×1012), AAV2/5-EFS-GFP (1.0×1012), AAV2/2-
EFS-REP1 (1.4×1012), AAV2/5-EFS-REP1 (1.0×1012),
AAV2/2-CBA-GFP (1.1×1012) and AAV2/2-CBA-REP1
(1.1×1012).
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Transduction of the cultured cells
Dog osteosarcoma D17 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10 % foetal bovine serum (FBS). Human CHM fibroblasts
with full deletion of CHM/REP1 gene and control fibroblasts
were obtained from Ian MacDonald (University of
Alberta, Canada). CHM and control fibroblasts were cultured
in DMEM/F12+15 % FBS+2 mM L-glutamine + penicillin/
streptomycin. Prior to transduction cells were plated into 12-
well dish (D17 cells at 7.5×104 cells per well and CHM cells
at 3×104 cells per well). The next day medium was removed,
cells were washed with PBS and 1 ml of Iscove’s modified
Dulbecco’s medium (IMDM) supplemented with 10 mM
hydroxyurea was added to the wells for overnight treatment.
Cells were washed with IMDM twice, and 0.5 ml of IMDM +
viral vector (109gp) was added to the cells for 2 h, followed by
addition of 0.5 ml of IMDM+20 % FBS.
Immunoblotting and in vitro prenylation assay
The protocol for immunoblotting has been described previously
[11]. Antibodies used in the current study were: mouse monoclo-
nal 2F1 (specific for humanREP1, dilution 1:1,000); rabbit serum
J905 (pan-REP, specific for mouse, rat and human isoforms of
REP1 and REP2); mouse monoclonal α-tubulin (Sigma, dilution
1:5,000) and mouse monoclonal anti-GFP (Zymed, dilution
1:2,000). Quantification of western blots was performed with
ImageJ software. Plots show Optical Density and Relative
Density (%) which is Optical Density normalised to α-tubulin
signal in the same lane (Relative Density=Optical Density×
100/Optical Density forα-tubulin). The in vitro prenylation assay
was performed on cytosolic fractions of tissue and cell lysates that
were collected after ultracentrifugation (100,000×g, 1 h, 4 °C) as
described in [11]. Quantification of the exposed film was
performed with ImageJ software.
Cultures of ex vivo retinal transplants
UK Research Ethics Committee (REC) approval was
obtained to culture samples of retina ex vivo from patients
undergoing retinectomy for complex retinal detachment sur-
gery (REC reference no. 10/H0505). A 23-gauge pars plana
vitrectomy was performed for complex retinal detachment
surgery which required removal of retinal tissue inferiorly
(retinectomy). Discs of the retina were cut with the vitrec-
tomy system at a slow rate of 60 cuts/min (Ocutome; Alcon
Surgical, Irvine, TX, USA), refluxed into the eye, aspirated
with a flute needle and placed in balanced salt solution.
Within 1 h of removal from the eye, the retinectomy samples
were transferred using a 5-ml pipette into four organotypic
culture inserts (cat. no. 353095; BD Falcon, Bedford, MA,
USA) and placed in a 24-well plate. Samples were cultured
in 700 μl of culture media containing Neurobasal A, L-
glutamine (0.08 mM), penicillin (100 U/ml), streptomycin
(100 U/ml), B27 supplement (2 %) and N2 supplement
(1 %), all obtained from Invitrogen Ltd., Paisley, UK [19].
Explants were maintained at 34 °C in a 5 % CO2 environ-
ment. After 24 h, medium was changed and 10 μl of
AAV2/2-CBA-GFP (titre 1×1012gp/ml) was added to each
well, with two wells tested per virus. Culture medium was
changed every 48 h, and explants were imaged daily on an
inverted epifluorescence microscope (DMIL; Leica, Wetzlar,
Germany). Explants were fixed 11 days post-transduction in
4 % paraformaldehyde overnight, cryoprotected in 20 %
sucrose for 1 h, embedded in OCT compound (Tissue-Tek,
Sakura Finetek, the Netherlands) and frozen on dry ice.
Explants were cut into 16 μm, counterstained with anti-
recoverin primary antibody (Millipore, dilution 1:1,000),
secondary Alexa 633 (Invitrogen, dilution 1:300) and
DAPI (ProLong Gold antifade reagent with DAPI, Invi-
trogen, Paisley, UK) and viewed on a confocal microscope
(LSM710; Zeiss, Jena, Germany). The retinal explant in
Fig. 4 was from a 40-year-old gentleman who required reti-
nectomy for chronic retinal detachment following endogenous
Klebsiella endophthalmitis. A similar transduction pattern
with the vector was also seen in a retinal explant sample from
a 60-year-old lady who required retinectomy for a chronic
retinal detachment with proliferative vitreoretinopathy that
had previously been treated with vitrectomy, silicone oil and
scleral buckle.
Subretinal injections and morphological study
Mice were anaesthetised with a mixture of Domitor/ketamine;
pupils were dilated with phenylephrine hydrochloride (2.5 %)
and tropicamide (1%). Proxymetacaine hydrochloride (0.5%)
eye drops were used for additional local anaesthesia; carbomer
gel (Viscotears, Novartis Pharmaceuticals Ltd) and a small
circular glass coverslip were used to achieve good visualisa-
tion of the fundus. The injection was performed through
posterior retina using 10-μl Hamilton syringe and a pointed
34G needle. Mouse eyes for histology were fixed in 4 %
paraformaldehyde for 1 h. Samples were cryoprotected in
20 % sucrose overnight and embedded in the OCT compound
(BDH Poole, Dorset, UK). Sections were cut at 7 μm
thickness, air-dried, covered with mounting media Prolong
Gold and examined under a Zeiss LSM-510 inverted confocal
microscope.
ERG analysis
Before the electroretinogram (ERG) procedure, mice were
dark adapted (>1 h), and experimental preparation was
performed under dim red illumination. The mice were
anaesthetised with a single intraperitoneal injection of
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medetomidine hydrochloride (Domitor; 1 mg/kg body
weight) and ketamine (60 mg/kg body weight) in water.
The pupils were dilated using 1 % tropicamide eye drops.
ERGs were recorded using an electroretinography console
(Espion E2; Diagnosys LLC, Cambridge, UK) that also
generated and controlled the light stimulus. Single-flash
stimuli were delivered in a Ganzfeld dome with the intensity
increasing from −6 to 1 log cds/m2 in log unit steps. For dim
stimuli (−6 and −5 log cds/m2), 20 responses were averaged
with an interstimulus interval (ISI) of 2 s. For stimuli of −4
and −3 log cds/m2, 20 responses were averaged with an ISI
of 5 s; for stimuli of −2 and −1 log cds/m2, ten responses
were averaged with an ISI of 10 s. For bright stimuli (0 and
1 log cds/m2), five responses were averaged with an ISI of
20 s. After dark-adapted recordings were completed,
animals were exposed to a full field 30 cd/m2 white
background for 10 min. Light-adapted ERGs were then
recorded in response to a bright white stimulus (1 log
cds/m2, 20 responses averaged, ISI=500 ms) superimposed
on the constant background. ERGs were recorded from both
eyes simultaneously using custom-made active electrodes
(platinum wire loop type) positioned concentrically to the
cornea using micromanipulators. Hypromellose eye drops
(0.5 % methylcellulose solution) were used to provide good
electrical contact and to maintain corneal moisture. A
reference electrode (subcutaneous stainless steel needle)
was placed in the scruff, and an identical ground electrode was
positioned at the base of the tail. All recordings were made in a
custom-made, light-tight Faraday cage. Signals were differen-
tially amplified and digitized at a rate of 5 kHz. Amplitudes of
the major ERG components (a- and b-waves for dark-adapted,
b-wave only for light-adapted) weremeasured (Espion software;
Diagnosys LLC) using automated and manual methods.
Results
Generation of AAV viral vectors
As a candidate promoter, we tested two ubiquitous promoters
that were shown to be active in RPE and photoreceptors:
elongation factor 1-α promoter (shortened version, EFS) and
CMV-enhanced chickenβ-actin promoter (CBA) [20, 21]. As a
therapeutic gene, we usedCHM/REP1 cDNAwith an upstream
Kozak sequence that was previously shown to be functionally
expressed from the lentiviral backbone [11]; the EGFP gene
was employed as a control transgene (Fig. 1a). To enhance
transgene expression, all vectors contained aWPRE next to the
3′-end of the transgene followed by a polyadenylation signal
site. EFS and CBA plasmids carrying CHM/REP1 cDNA or
EGFP transgene were used to generate AAV vectors of
serotype 2 and serotype 5 that were previously shown
to transduce RPE and photoreceptors [22].
Expression of CHM/REP1 cDNA and EGFP transgenes
in D17 cells
Initially, the AAV2/2-EFS-GFP, AAV2/5-EFS-GFP and
AAV2/2-CBA-GFP vectors were tested by transduction of
dog osteosarcoma D17 cells. Expression of GFP was
detected 2 days post-transduction (P0) by FACS (Fig. 1b)
and immunoblotting using anti-GFP antibody (Fig. 1c, d).
The cells were passaged and expression was tested after
6 days (8 days post-transduction, P1) and then 4 days after
the second passage (12 days post-transduction, P2). Transduc-
tion rate (percentage of GFP-positive cells at P0) was similar
for AAV2/2-EFS-GFP and AAV2/2-CBA-GFP (17.7 and
17.3 %, respectively) and lower (12.5 %) for AAV2/5-EFS-
GFP (Fig. 1b). The prevalence of GFP-expressing cells de-
creased with each passage for all three vectors (at P1: 9.2 %
for AAV2/2-EFS-GFP, 9.1 % for AAV2/2-CBA-GFP, 8 % for
AAV2/5-EFS-GFP), which is consistent with the episomal
non-replicating status of the AAV vector and proportional
decrease in copy number with each cell division (Fig. 1b).
Western blot analysis showed robust transgene expression
from both EFS and CBA promoters, with expression from
CBA being slightly higher than from EFS: 150 and 107 %,
respectively, at P0, 139 and 102% at P1 and 33 and 21% at P2
(Fig. 1d).
Having optimised the viral transduction using the GFP
reporter, we transduced D17 cells with AAV2/2-EFS-REP1,
AAV2/5-EFS-REP1 and AAV2/2-CBA-REP1 vectors carry-
ing the CHM/REP1 cDNA transgene, and the amount of
REP1 was detected by immunoblotting using 2F1 antibody
specific for human REP1 2 days post-transduction (Fig. 1e).
Unlike GFP, expression of REP1 from the CBA promoter was
considerably stronger than from the EFS promoter: 156.5
versus 26.9 % for AAV2/2-EFS-REP1 and 23.8 % for
AAV2/5-EFS-REP1 (Fig. 1f).
Thus, our data show that viral vectors of both serotypes
(2 and 5) were able to transduce D17 cells. As expected,
expression of both transgenes (CHM/REP1 and EGFP) in
D17 cells was transient due to the episomal status of the
vector. Expression from both EFS and CBA promoters was
detected as early as 2 days post-transduction and was higher
from CBA promoter than from EFS (especially for the
CHM/REP1 transgene).
Expression of CHM/REP1 cDNA and EGFP transgenes
in CHM fibroblasts
To confirm that CHM/REP1 transgene expression is not im-
paired in CHM cells, we used fibroblasts from a CHM patient
with full deletion of the CHM/REP1 gene [23]. CHM fibro-
blasts were transduced with AAV2/2-EFS, AAV2/5-EFS and
AAV2/2-CBA vectors carrying EGFP or CHM/REP1 cDNA
transgenes. Expressionwas detected by immunoblotting using
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an anti-GFP antibody (Fig. 2a) and anti-human REP1 anti-
body (Fig. 2b). For both EGFP and REP1, expression levels
were significantly higher with the CBA promoter in comparison
to EFS.
Our results identified that the CBA promoter provided a
considerably higher level of expression in CHM cells. To
measure level of CBA-driven expression of REP1 in trans-
duced cells in comparison to endogenous REP1 in control
wild-type (WT) fibroblasts, we transduced human CHM
fibroblasts with AAV2/2-CBA-REP1 and compared amount
of REP1 using 2F1 antibody (Fig. 2c). Quantification of the
western blot showed that the intensity of the REP1-specific
band in 40 μg of WT lysate was roughly equal to the
intensity of REP1 band in 5 μg of lysate from transduced
cells (CHM AAV2/2-CBA-REP1) (Fig. 2d). Thus, the level
of expression of REP1 protein under these conditions was
approximately eight times higher than endogenous REP1 in
control fibroblasts, confirming that the REP1 defect does
not prevent successful AAV2/2-mediated transduction and
transgene expression.
The functionality of the REP1 transgene was tested by an
in vitro prenylation assay in CHM fibroblasts and D17 cells
(Fig. 2e, f). In both cell types, we observed an increase in
prenylation activity in the cytosolic lysate from cells trans-
duced with AAV2/2-CBA-REP1 in comparison to untrans-
duced cells or cells transduced with the AAV2/2-CBA-GFP
control vector, confirming expression and functionality of
the CHM/REP1 transgene.
Expression of CHM/REP1 cDNA and EGFP transgenes
in mouse retina
To deliver AAV vectors into the mouse retina, we used a
posterior trans-scleral approach (Fig. 3a, b). To verify
Fig. 1 Expression of CHM/REP1 cDNA and EGFP transgenes in dog
D17 cell line. a Plasmids pAAV2-EFS-REP1 and pAAV2-CBA-REP1
carry the CHM/REP1 cDNA transgene with Kozak sequence at the 5′-
end. Plasmids pAAV2-EFS-GFP and pAAV2-CBA-GFP were used to
generate control viral vectors. WPRE* is a WPRE that has been
modified by deleting the We2 promoter/enhancer and mutating the
We1 promoter (for other details, see “Materials and methods”). b–d
D17 cells were transduced with AAV2/2-EFS-GFP, AAV2/5-EFS-GFP
and AAV2/2-CBA-GFP. Expression of GFP was analysed 2 days post-
transduction (P0). Cells were replated, cultured for additional 6 days
and analysed (P1), then replated and analysed after 4 days in culture
(P2). b FACS analysis shows prevalence of transduced cells (% of total
cell number). c Immunoblot analysis of the total protein lysate using
GFP antibody and α-tubulin antibody as a loading control. d Quanti-
fication of the western blot shown in c using ImageJ software. Data are
presented as relative density of GFP signal in relation to α-tubulin
signal. e Immunoblot analysis of the D17 cells transduced with AAV2/
2-EFS-REP1, AAV2/5-EFS-REP1 and AAV2/2-CBA-REP1 using 2F1
antibody specific for human REP1 and α-tubulin antibody as a loading
control. Cells were analysed 48 h post-transduction. f Quantification of
the western blot shown in e using ImageJ software. Data are presented
as relative density of GFP signal in relation to α-tubulin signal
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expression of the CHM/REP1 cDNA transgene in the cho-
roideremia mouse retina, AAV2/2-EFS-REP1, AAV2/5-
EFS-REP1 and AAV2/2-CBA-REP1 vectors were injected
subretinally into Chmnull/WT female carriers. The contralat-
eral eye was not injected and served as a control. The RPE
was collected 5 weeks post-injection from injected and non-
injected eyes, and expression of REP1 was analysed by
western blotting using 2F1 antibody, specific for human
REP1. We observed a strong signal in the RPE from the
eyes injected with AAV2/2-CBA-REP1 and a very faint
signal after injection with AAV2/5-EFS-REP1 (Fig. 3c).
These in vivo data, therefore, confirmed that AAV2/2-
CBA-REP1 provided the highest level of the three tested
viral vectors in the mouse RPE.
To confirm that the AAV2/2-CBA-WPRE expression
cassette mediated expression in mouse photoreceptors as
well as in the RPE, we injected 3–4-week-old wild-type
mice with 1 μl of the AAV2/2-CBA-GFP viral vector con-
taining 1×109gp (Fig 3d–f). Within the transduced regions,
we observed extensive labelling of photoreceptor cells in the
outer nuclear layer in addition to labelling of the RPE, thus
confirming suitability of AAV2/2-CBA-WPRE vector for
transgene expression in both layers.
Expression of AAV2/2-CBA-GFP in human retinal explants
To confirm that AAV2/2-CBA-WPRE expression cassette
was capable of transducing human photoreceptors in human
Fig. 2 a Immunoblot analysis of choroideremia patient fibroblasts
(CHM) transduced with AAV2/2-EFS-GFP, AAV2/5-EFS-GFP and
AAV2/2-CBA-GFP using GFP antibody and α-tubulin antibody as a
loading control. Expression of GFP was analysed 7 days post-
transduction. b Immunoblot analysis of CHM transduced with AAV2/
2-EFS-REP1, AAV2/5-EFS-REP1 and AAV2/2-CBA-REP1 using 2F1
antibody and α-tubulin antibody as a loading control. Expression of
REP1 was analysed 7 days post-transduction. c Immunoblot analysis of
choroideremia patient fibroblasts that were untransduced (CHM) and
transduced with AAV2/2-CBA-REP1 and control (WT) fibroblasts using
2F1 antibody and α-tubulin antibody as a loading control. Expression of
REP1 was analysed 10 days post-transduction. Amount of loaded cell
lysate (micrograms) is indicated above each lane. Recombinant human
protein (hREP1) was used as a positive control. d Quantification of the
GFP signal intensity from the western blot shown in c using ImageJ
software. e In vitro prenylation analysis was performed using 5
and 20 μg of cytosolic fractions of the cell lysates isolated from
untransduced (white diamond) and transduced with AAV2/2-CBA-
GFP (black square) and AAV2/2-CBA-REP1 (white triangle)
CHM fibroblasts. f In vitro prenylation analysis was performed
using 2, 4, 8 and 16 μg of cytosolic fractions of the cell lysates
isolated from untransduced D17 cell (white diamond) and D17
transduced with AAV2/2-CBA-GFP (black square) and AAV2/2-
CBA-REP1 (white triangle)
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retina, we cultured human retinal explants ex vivo and
infected them with the AAV2/2-CBA-GFP vector. Expres-
sion of the GFP transgene was assessed 11 days post-
transduction. Frozen sections of explants were stained with
anti-recoverin antibody and DAPI and analysed by confocal
microscopy (Fig. 4). In EGFP-positive cells, we observed a
strong signal with anti-recoverin antibody which confirmed
transduction of photoreceptors of cultured explants.
Effects of REP1 overexpression on retinal function
in wild-type mice
To examine whether REP1 overexpression might be toxic,
subretinal injections of 1×109gp (1 μl of undiluted suspen-
sion at 1×1012gp/ml) of AAV2/2-CBA-REP1 were per-
formed on control wild-type mice (n=5) at 4 weeks of
age. In all cases, the contralateral eye received an equivalent
dose subretinal injection of AAV2/2-CBA-GFP to act as an
internal control for non-transgene-specific effects. Retinal
function was assessed using ERG recording 6 months post-
injection. In AAV2/2-CBA-REP1-treated eyes, clear dark-
adapted ERG responses could be recorded across a 7 log
unit range of flash intensity (Fig. 5a, black lines). Responses
from AAV2/2-CBA-GFP-injected control eyes were also
present across the same range, but slightly smaller in ampli-
tude (Fig. 5a, grey lines). Quantification of the amplitude of
the a- and b-waves of the ERG confirmed this observation
(Fig. 5b). For a-wave amplitude, a two-way repeated-
measures ANOVA with treatment and intensity as factors
found that both were highly significant (p<0.0001 for both),
and Bonferroni post hoc tests indicated significant pairwise
differences in the three highest intensities tested (−1 to 1 log
cds/m2). For b-wave amplitude, a similar analysis (two-way
repeated-measures ANOVA) also found intensity and treat-
ment to be highly significant (both p<0.0001) factors, and
Bonferroni post-tests revealed significant pairwise differen-
ces in all but the lowest two intensities. Despite differences
in the amplitudes of both a- and b-waves, the kinetics of
dark-adapted ERGs did not appear to be grossly altered
(Fig. 5a). Quantification and statistical analysis of the
implicit time of the a- and b-waves (Fig. 5c) found that
they were not significantly different (two-way repeated-
measures ANOVAwith treatment and intensity as factors were
p>0.05 in all cases).
In a related experiment, performed using a single 1-μl
injection of 1:10 dilution of the viral vector (dose of 1×108
gp) for both AAV2/2-CBA-REP1 and AAV2/2-CBA-GFP),
clear dark-adapted ERGs could again be recorded (not
Fig. 3 a, b Illustration of delivery route for AAV viral vectors by
subretinal injection. The subretinal injection was performed through
posterior retina using a 10-μl Hamilton syringe and a 30° bevelled 34G
needle. c Immunoblot analysis of RPE collected from the eyes of
choroideremia mice (Chmnull/WT) injected with AAV2/2-EFS-REP1,
AAV2/5-EFS-REP1 and AAV2/2-CBA-REP1 using 2F1 antibody
and α-tubulin antibody as a loading control. Expression of REP1 was
analysed 5 weeks post-injection. d–f Histological analysis of the
AAV2/2-CBA-GFP-injected mouse eyes 5 weeks post-injection. e
Phase contrast image corresponding to d. f Enlargement image of the
area boxed in d. Arrows indicate nuclei of rod photoreceptors that
express GFP confirming successful transduction. RPE retinal pigment
epithelium, ONL outer nuclear layer, IS inner segments, OS outer
segments. Bar is 50 μm
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shown). However, response amplitudes were now almost
identical in both eyes (Fig. 5d) and very similar to those
obtained after high titre AAV2/2-CBA-REP1 injections.
Waveform kinetics were indistinguishable between eyes
(not shown). Quantification and statistical analysis of the
a- and b-wave implicit times confirmed that they were not
significantly different between eyes (two-way repeated-
measures ANOVA with treatment and intensity as factors
were p>0.05 in all cases; Fig. 5e).
Light-adapted ERGs recorded in the same animals as above
showed a similar pattern of results (Fig. S1). In high-dose (1×
109gp) AAV2/2-CBA-REP1-treated eyes, characteristic light-
adapted ERG waveforms could be recorded (Fig. S1). Again,
responses from high-dose (1×109gp) AAV2/2-CBA-GFP-
injected control eyes were present, but there was a significant
reduction in b-wave amplitude (Fig. S1). As a consequence of
the reduction in amplitude, responses also appeared to be
slightly faster (significantly reduced b-wave implicit time).
Light-adapted ERGs in low-dose (1×108gp) AAV2/2-CBA-
REP1-treated eyes were indistinguishable from those of
low-dose (1×108gp) AAV2/2-CBA-GFP-injected control
eyes almost identical to those obtained after high titre
AAV2/2-CBA-REP1 injection (Fig. S1).
Overall, high-dose (1×109gp) or low-dose (1×108gp)
AAV2/2-CBA-REP1 subretinal injections did not lead to
evident impairment of retinal function in wild-type mice.
At the same time, responses for high-dose AAV2/2-CBA-
GFP-treated eyes were reduced, suggesting that high level
of GFP expression might lead to inhibitory effect on ERG
responses. Hence, these experiments confirmed that no
obvious toxic effects on retinal function were evident fol-
lowing overexpression of REP1, even at a vector dose
sufficiently high to show clearly detectable toxic effects
of GFP.
Effects of REP1 overexpression on retinal function
in Chmnull/WT mice
Heterozygous female carriers (Chmnull/WT) have been shown
previously to display progressive retinal degeneration with a
Fig. 4 Expression of pAAV2/2-CBA-GFP in human retinal explants.
Explants from a 40-year-old gentleman who required retinectomy for
chronic retinal detachment following endogenous Klebsiella endoph-
thalmitis were maintained ex vivo and transduced with pAAV2/2-
CBA-GFP; 11 days post-transduction explants were fixed in 4 %
paraformaldehyde, cryoprotected in 20 % sucrose and frozen in OCT.
Sections were stained with anti-recoverin primary and Alexa-633
secondary antibody and DAPI. b Merged signals for recoverin (red)
and EGFP (green) are shown. c–f Enlargements of the area 1 boxed in
a. g–j Enlargement of the area 2 boxed in a. d, h Recoverin-specific
staining, converted to greyscale. e, i EGFP signal, converted to grey-
scale. f, j DAPI staining, converted to greyscale. Asterisks indicate
cells positive for EGFP and recoverin markers. ONL outer nuclear
layer, INL inner nuclear layer. Bar is 50 μm
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clear reduction of the dark-adapted ERG amplitude [15]. To
explore the potential of CHM/REP1 gene therapy to ame-
liorate retinal function, Chmnull/WT mice were treated with
two 1-μl injections in superior and inferior areas (2 μl total)
of AAV2/2-CBA-REP1 at 4 weeks of age. Subretinal injec-
tions with DMEM medium (1 μl) were performed on the
contralateral eye of each animal, to act as an internal control
for surgical sham effects. ERG recording was performed
6 months later, and responses were compared between
vector- and sham-treated eyes. Recordings in groups that
received high (2×109gp, n=5) and low (1:10 dilution in
DMEM, 2×108gp, n=5) dose of AAV2/2-CBA-REP1 were
compared to those from a contralateral sham-treated control
eye in each case. In both sham- and high-dose treated eyes
of Chmnull/WT mice, intensity-dependent, dark-adapted ERG
responses could be recorded (Fig. 6a). Responses from high-
dose AAV2/2-CBA-REP1-treated eyes appeared to be larger
in amplitude than from contralateral sham-treated eyes.
Quantification of the amplitude of the a- and b-waves of
the ERG supported this observation (Fig. 6b). For a-wave
amplitude, a two-way repeated-measures ANOVA with
treatment and intensity as factors found that both were
significant (p=0.0071 for treatment, p<0.0001 for intensity).
Bonferroni post-tests showed a significant (p<0.001) pairwise
difference at the highest intensity (1 log cds/m2) only.
For b-wave amplitude, a two-way repeated-measures
ANOVA analysis found both factors to be highly significant
(p=0.0005 for treatment, p<0.0001 for intensity), but
Bonferroni post-tests did not indicate any significant
differences in pairwise comparison at any individual
intensity. Quantification of the a- and b-wave implicit
times of the ERG indicated that, while there was a
strong intensity dependent effect, this was not different
between AAV2/2-CBA-REP1 and sham eyes (Fig. 6c).
Conversely, quantification of ERGs in Chmnull/WT eyes
treated with a lower dose (2×108gp) of AAV2/2-CBA-
REP1 did not show improvement of the retinal function
(Fig. 6d). There was a slight reduction in the amplitude of
a- and b-waves compared to fellow sham-treated eyes,
which could be due to a two times lower volume of sham
Fig. 5 ERG analysis of wild-type mice treated with AAV2/2-CBA-
REP1 and AAV2/2-CBA-GFP. a Representative averaged ERG traces
from the eyes injected with high-dose (1×109gp) AAV2/2-CBA-REP1
(shown in black) and AAV2/2-CBA-GFP (shown in grey). b, c Quan-
tification of the amplitude of a- and b-waves (b) and implicit time data
(c) recorded across a range of stimulus intensities in high-dose (1×109
gp) AAV2/2-CBA-REP1-injected (filled black circles and solid black
lines) and AAV2/2-CBA-GFP-injected (open grey circles and dashed
grey lines) eyes. Plotted symbols show mean±SEM, n=5. d, e Quan-
tification of the amplitude of a- and b-waves (d) and implicit time data
(e) recorded across a range of stimulus intensities in low-dose (1×108
gp) AAV2/2-CBA-REP1-injected (filled black circles and solid black
lines) and AAV2/2-CBA-GFP-injected (open grey circles and dashed
lines) eyes. Plotted symbols show mean±SEM, n=4
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injection (1 μl) versus 2 μl for the viral injection. A two-
way repeated-measures ANOVA for a-wave amplitude with
treatment and intensity as factors found that both were
significant (p=0.0011 for treatment, p<0.0001 for intensi-
ty). Bonferroni post-tests showed a significant (p<0.05)
pairwise difference at 0 log cds/m2 intensity only. For b-
wave amplitude, a two-way repeated-measures ANOVA
analysis found both treatment (p=0.004) and intensity
(p<0.0001) to be highly significant factors, but Bonferroni
post-tests did not indicate any significant differences in a
pairwise comparison at any individual intensity. Quantifica-
tion of the a- and b-wave implicit times of the ERG indicated
that response kinetics were not different between AAV2/2-
CBA-REP1 and sham eyes (Fig. 6e).
Fig. 6 ERG analysis of Chmnull/WT mice, treated with AAV2/2-CBA-
REP1 and DMEM (sham). a Representative averaged ERG traces from
high-dose (2×109gp) AAV2/2-CBA-REP1-injected (shown in black)
and sham-injected (shown in grey) eyes. b, c Quantification of the
amplitude of a- and b-waves (b) and implicit time data (c) recorded
across a range of stimulus intensities in high-dose (2×109gp) AAV2/2-
CBA-REP1-injected (filled black circles and solid black lines) and
sham-injected (open grey circles and dashed lines) eyes. Plotted sym-
bols show mean±SEM, n=5. d, e Quantification of the amplitude of a-
and b-waves (d) and implicit time data (e) recorded across a range of
stimulus intensities in low-dose (2×108gp) AAV2/2-CBA-REP1-
injected (filled black circles and solid black lines) and sham-injected
(open grey circles and dashed lines) eyes. Plotted symbols show
mean±SEM, n=5. f, g Change in a-wave (f) and b-wave (g)
amplitude in high-dose (2×109gp, filled black circles) and low-
dose (2×108gp, open grey circles) AAV2/2-CBA-REP1 treatment
groups. Individual values shown as point and group means as
connecting lines
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Importantly, ERG amplitudes expressed as a difference in
the AAV2/2-CBA-REP1-treated eye compared to the con-
trol eye in each individual (Fig. 6f, g) illustrate improvement
in the high dose (individual values and mean above zero)
and reduction or no effect with low dose (values at or below
zero) for both a-wave (Fig. 6f) and b-wave (Fig. 6g).
Light-adapted ERGs were recorded in most of the
groups/animals above. With the exception of two individu-
als (where electrode stability deteriorated and they were not
continued), distinct light-adapted ERG waveforms were ob-
served (Fig. S2). However, unlike in dark-adapted ERG, no
differences could be found in response amplitude between
AAV2/2-CBA-REP1-injected and sham-treated eyes in ei-
ther the low- or high-dose experiments (Fig. S2). A deficit in
the light-adapted ERGs of Chmnull/WT animals relative to
wild-type controls has not been fully investigated. Conse-
quently, a possible reason for the lack of any detectable
improvement in high-dose AAV2/2-CBA-REP1-injected
eyes may be the absence of an appropriate phenotype to
rescue.
Therefore, a dose-related effect of AAV2/2-CBA-REP1
injection could be seen on both the a- and b-wave amplitude
of dark-adapted ERGs from Chmnull/WT retinas. High-dose
AAV2/2-CBA-REP1 treatment appeared to improve dark-
adapted retinal function in Chmnull/WT mice, whereas low-
dose AAV2/2-CAG-REP1 injection did not have such an
effect.
Discussion
CHM would be an ideal candidate disease for gene therapy
treatment due to the slow rate of degeneration and a rela-
tively small size (1.9 kb) of the CHM/REP1 coding se-
quence that can be used as a potential therapeutic
transgene in an AAV vector. We have shown previously that
in CHM, pathological changes appear in photoreceptors and
RPE autonomously, and therefore, both layers need to be
treated simultaneously [5]. To achieve this, we used an
AAV2-based vector, which was reported to transduce both
photoreceptors and RPE [14]. In comparison to the lentiviral
vectors that we used in the past, AAV vectors were able to
transduce RPE efficiently and were much more potent in
transduction of the neuroretinal cells that were transduced
with the lentiviral vectors only in the vicinity of the injection
site [11, 24]. Seemingly, AAV vectors are more adept at
navigating through the tightly packed area of photoreceptor
outer segments, in a direction that is opposite to shedding of
photoreceptor outer segments. A possible explanation of a
higher penetrating ability could be a much smaller size of a
mature AAV virion (20 nm), in comparison to the lentiviral
particle (145 nm), that would potentially allow an AAV
particle to disseminate more easily.
The ubiquitous pattern of REP1 expression provided us
with the opportunity to use fibroblasts harvested from the
CHM patients for the functional evaluation of the transgene
expression. In future, this approach may be applied to other
retinal degenerations by deriving photoreceptors in vitro via
induced pluripotent stem cells [25] or transdifferentiation of
the RPE [26]. In addition to dog and mouse cells, human
choroideremia patient fibroblasts provided an extra species
in which we could demonstrate functionality of CHM/REP1
transgene expressed from our vector.
We compared two ubiquitous promoters, EFS and CBA,
and found that transgene expression from CBA was higher
than from EFS for both CHM/REP1 and EGFP transgenes
in human fibroblasts. One key difference between these two
promoters is the inclusion of the synthetic intron in the CBA
promoter upstream of the Kozak sequence at the 5′ untrans-
lated region of the transgene. Intron processing through
splicing is a feature of eukaryotic gene expression and
may significantly increase viral transgene expression in
certain circumstances [27]. Our data showed that CBA was
a more suitable promoter to achieve a high level of trans-
gene expression than EFS. To confirm functionality of the
CHM/REP1 transgene, we showed that transduction of cho-
roideremia patient fibroblasts with AAV2/2-CBA-REP1 led
to an increase in prenylation activity; a similar effect was
detected in dog D17 cells transduced with AAV2/2-CBA-
REP1. Thus, the AAV2/2-CBA-REP1 vector provides
strong and functional transgene expression.
Although CBA is a standard ubiquitous promoter, there are
cell types where it is not active, for example, cytotoxic T-
lymphocytes [28]. Primate experiments to date have more
commonly utilised the smaller CMV promoter in the retina
[14, 29], and absolute evidence that CBA drives efficient
transgene expression in human photoreceptors has been lack-
ing. Furthermore, a safety study using CBA to drive AAV2-
mediated RPE65 expression in cynomolgus monkeys failed to
detect ectopic RPE65 expression in photoreceptors even with
a relatively high dose of 4.5×1010gp, which was unexpected
[30]. In our study, to confirm that the CBA promoter can drive
transgene expression in human photoreceptors, we transduced
human retinal explants taken from patients undergoing retinal
detachment surgery ex vivo with AAV2/2-CBA-GFP that
contained an identical cassette to AAV2/2-CBA-REP1 vector.
Since the retinal explants were acquired from the patients with
a normal level of REP1, we decided that detection of trans-
gene expression would be more reliably confirmed if we used
an EGFP reporter gene as a marker of vector tropism in the
human retina in place of CHM/REP1 cDNA in an otherwise
identical expression cassette and AAV capsid. Ideally we
would wish to use CHM retinal explants; however, this was
not possible due to the rarity of CHM and absence of docu-
mented retinal detachment in these patients, which might
possibly be explained by firm adherence resulting from the
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degeneration. This experiment confirmed excellent transduc-
tion of human photoreceptors.
Potential toxicity of REP1 overexpression was assessed
by subretinal injection of wild-type mice with a high and a
low dose of AAV2/2-CBA-REP1 and AAV2/2-CBA-GFP.
Both dark- and light-adapted ERG responses in wild-type
eyes treated with a high or a low dose of AAV2/2-CBA-
REP1 were grossly normal and indistinguishable from
responses from eyes injected with a low dose of AAV2/2-
CBA-GFP, which suggests that AAV2/2-CBA-REP1 vector
is not toxic. At the same time, ERG responses in high-dose
AAV2/2-CBA-GFP-treated eyes were significantly attenuat-
ed, suggesting that a high level of GFP might be harmful to
retinal cells. The mechanism of GFP toxicity may relate to
an impairment of polyubiquitination [31], and hence,
AAV2/2-CBA-GFP may not be a reliable control vector to
gauge potential treatment effects of AAV2/2-CBA-REP1
vector on the CHM mouse ERG. For this reason, we used
DMEM, which controlled for any negative effects of retinal
detachment or positive sham effects of surgery in these
mice. Comparison of dark-adapted ERG responses from
AAV2/2-CBA-REP1- and sham-injected eyes from individ-
ual animals showed improvement of retinal function at high
dose of the vector, thus demonstrating therapeutic potential
of the vector.
The inclusion of a WPRE in our expression cassette is a
novel development in AAV-mediated retinal gene therapy
that has not been used in human retinal gene therapy clinical
trials to date. It has, however, been used in other studies,
such as in the AAV.GAD gene therapy study to treat Par-
kinson’s disease [18] and has been approved by the FDA for
phase II clinical trials. The inclusion of WPRE significantly
enhances AAV transgene expression in the rat brain [32], in
human embryonic kidney cells (HEK293) and human skin
fibroblasts in vitro by up to a log unit [33]. We used a
WPRE sequence previously modified to prevent expression
of the viral X antigen, which has previously been linked to
increased tumour susceptibility in the liver of mice [16, 34].
The advantage of using the WPRE together with an opti-
mised promoter is that enhanced transgene expression
would permit us to use a lower overall dose of AAV2 to
achieve a therapeutic effect. Although one might argue that
other serotypes such as AAV8 may be more efficient in
targeting photoreceptors, AAV2 with the CBA promoter
remains the gold standard for retinal transduction as
evidenced by the sustained vision in Briard dogs treated
with AAV2 vector over a decade ago [35]. Hence, valid
rationale is to increase the efficiency of AAV2 through
optimisation of the regulatory elements within the expres-
sion cassette, rather than changing the capsid. A combina-
tion of high therapeutic efficiency and low vector dose is
particularly relevant for a disease such as CHM. Firstly,
slow progression of CHM may indicate that a relatively
low level of transgene expression could achieve a therapeu-
tic effect. Secondly, low dose is particularly beneficial when
transduction of other cells (cones in the case of CHM) is
potentially undesirable.
In summary, our data show that AAV2/2-CBA-REP1
vector provides efficient, functional and non-toxic transgene
expression in the choroideremia mouse and human cells, as
well as in human and mouse RPE and photoreceptors.
AAV2/2-CBA-REP1vector has a small but detectable
dose-dependent therapeutic effect on retinal function in a
choroideremia mouse model and thus is a suitable therapeu-
tic agent for use in choroideremia clinical trials.
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